Yujeong Moon

1.2k total citations
24 papers, 949 citations indexed

About

Yujeong Moon is a scholar working on Biomedical Engineering, Oncology and Immunology. According to data from OpenAlex, Yujeong Moon has authored 24 papers receiving a total of 949 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Biomedical Engineering, 11 papers in Oncology and 9 papers in Immunology. Recurrent topics in Yujeong Moon's work include Nanoplatforms for cancer theranostics (17 papers), Immunotherapy and Immune Responses (9 papers) and Nanoparticle-Based Drug Delivery (8 papers). Yujeong Moon is often cited by papers focused on Nanoplatforms for cancer theranostics (17 papers), Immunotherapy and Immune Responses (9 papers) and Nanoparticle-Based Drug Delivery (8 papers). Yujeong Moon collaborates with scholars based in South Korea and Switzerland. Yujeong Moon's co-authors include Kwangmeyung Kim, Man Kyu Shim, Jinseong Kim, Suah Yang, Hanhee Cho, Jiwoong Choi, Hong Yeol Yoon, Wan Su Yun, Sukyung Song and Jeongrae Kim and has published in prestigious journals such as Advanced Materials, Angewandte Chemie International Edition and ACS Nano.

In The Last Decade

Yujeong Moon

24 papers receiving 938 citations

Peers

Countries citing papers authored by Yujeong Moon

Since Specialization

Citations

This map shows the geographic impact of Yujeong Moon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yujeong Moon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yujeong Moon more than expected).

Fields of papers citing papers by Yujeong Moon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yujeong Moon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yujeong Moon. The network helps show where Yujeong Moon may publish in the future.

Co-authorship network of co-authors of Yujeong Moon

This figure shows the co-authorship network connecting the top 25 collaborators of Yujeong Moon. A scholar is included among the top collaborators of Yujeong Moon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yujeong Moon. Yujeong Moon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Dual Delivery of Light/Prodrug Nanoparticles Using Tumor-Implantable Micro Light-Emitting Diode on an Optofluidic System for Combinational Glioma Treatment 2025 ·ACS Nano ·Jung-Suk Goo, (unknown), (unknown), Seong Ik Jeon, Jeongrae Kim, Wan Su Yun, (unknown), Yujeong Moon, (unknown), Jinseong Kim, Hanhee Cho, (unknown), (unknown), (unknown), Hyeon-Ju Lee, Won‐Gun Koh, (unknown), Tae‐il Kim, Kwangmeyung Kim	2
2	Effective Degradation of Wild‐Type and Mutant EGFR Using Self‐Assembling Peptide‐Derived PROTAC Nanoparticles (NanoTACs) for Cancer Therapy 2025 ·Advanced Materials ·(unknown), Hanhee Cho, Yujeong Moon, (unknown), Jeongrae Kim, Jinseong Kim, Sung-Chan Choi, Junseong Park, Yongju Kim, Kwangmeyung Kim	1
3	Self‐Assembled Peptide‐Derived Proteolysis‐Targeting Chimera (PROTAC) Nanoparticles for Tumor‐Targeted and Durable PD‐L1 Degradation in Cancer Immunotherapy 2024 ·Angewandte Chemie ·Yujeong Moon, Hanhee Cho, Jinseong Kim, Sukyung Song, Jung Yeon Park, (unknown), Eun Hee Han, Yongju Kim, (unknown), Man Kyu Shim, Kwangmeyung Kim	2
4	Nano-Delivery of Immunogenic Cell Death Inducers and Immune Checkpoint Blockade Agents: Single-Nanostructure Strategies for Enhancing Immunotherapy 2024 ·Pharmaceutics ·Yujeong Moon, Hanhee Cho, Kwangmeyung Kim	5
5	Implantable MicroLED‐Mediated Chemo‐Photodynamic Combination Therapy for Glioma Treatment 2024 ·Advanced Functional Materials ·Jeongrae Kim, (unknown), (unknown), Seong Ik Jeon, (unknown), Wan Su Yun, Yujeong Moon, Jiwoong Choi, Man Kyu Shim, Jinseong Kim, Hanhee Cho, (unknown), (unknown), Gyan Raj Koirala, (unknown), (unknown), Dong‐Hwee Kim, Won Seok Chang, Tae‐il Kim, Kwangmeyung Kim	15
6	Accurately Controlled Tumor Temperature with Silica-Coated Gold Nanorods for Optimal Immune Checkpoint Blockade Therapy 2024 ·Biomaterials Research ·Wan Su Yun, Wonseok Yang, Man Kyu Shim, Sukyung Song, Jiwoong Choi, Jeongrae Kim, Jinseong Kim, Yujeong Moon, (unknown), Dong‐Kwon Lim, (unknown)	4
7	Cancer cell-specific and pro-apoptotic SMAC peptide-doxorubicin conjugated prodrug encapsulated aposomes for synergistic cancer immunotherapy 2024 ·Journal of Nanobiotechnology ·Jinseong Kim, Man Kyu Shim, Yujeong Moon, Jeongrae Kim, Hanhee Cho, Wan Su Yun, (unknown), Joon‐Kyung Seong, Yonghyun Lee, Dong-Kwon Lim, Kwangmeyung Kim	17
8	All-in-one glycol chitosan nanoparticles for co-delivery of doxorubicin and anti-PD-L1 peptide in cancer immunotherapy 2023 ·Bioactive Materials ·Sukyung Song, Man Kyu Shim, Suah Yang, (unknown), Wan Su Yun, Hanhee Cho, Yujeong Moon, (unknown), Eun Hee Han, Hong Yeol Yoon, Kwangmeyung Kim	50
9	Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy 2023 ·Pharmaceutics ·Yujeong Moon, Seong Ik Jeon, Man Kyu Shim, Kwangmeyung Kim	30
10	Photo-induced crosslinked and anti-PD-L1 peptide incorporated liposomes to promote PD-L1 multivalent binding for effective immune checkpoint blockade therapy 2023 ·Acta Pharmaceutica Sinica B ·Youngjoo Lee, Sukyung Song, Suah Yang, Jinseong Kim, Yujeong Moon, (unknown), Hong Yeol Yoon, Sehoon Kim, Man Kyu Shim, Kwangmeyung Kim	15
11	Implantable micro-scale LED device guided photodynamic therapy to potentiate antitumor immunity with mild visible light 2022 ·Biomaterials Research ·Jiwoong Choi, (unknown), Ju Seung Lee, Sangmin Jeon, Wan Su Yun, Suah Yang, Yujeong Moon, Jinseong Kim, Jeongrae Kim, Seunghwan Choy, Chanho Jeong, Man Kyu Shim, Tae‐il Kim, Kwangmeyung Kim	24
12	Tumor-Specific Monomethyl Auristatin E (MMAE) Prodrug Nanoparticles for Safe and Effective Chemotherapy 2022 ·Pharmaceutics ·Hanhee Cho, Man Kyu Shim, Yujeong Moon, Sukyung Song, Jinseong Kim, Jiwoong Choi, Jeongrae Kim, Young Ju Lee, Jung Yeon Park, Yongju Kim, Cheol‐Hee Ahn, Mi Ra Kim, Hong Yeol Yoon, Kwangmeyung Kim	13
13	Sustained and Long-Term Release of Doxorubicin from PLGA Nanoparticles for Eliciting Anti-Tumor Immune Responses 2022 ·Pharmaceutics ·Jeongrae Kim, Yongwhan Choi, Suah Yang, (unknown), Jiwoong Choi, Yujeong Moon, Jinseong Kim, (unknown), Hanhee Cho, Man Kyu Shim, Sangmin Jeon, Dong‐Kwon Lim, Hong Yeol Yoon, Kwangmeyung Kim	23
14	Preclinical development of carrier-free prodrug nanoparticles for enhanced antitumor therapeutic potential with less toxicity 2022 ·Journal of Nanobiotechnology ·Man Kyu Shim, Suah Yang, Jooho Park, Jun Sik Yoon, Jinseong Kim, Yujeong Moon, (unknown), (unknown), Yongwhan Choi, Kwangmeyung Kim	19
15	Cathepsin B-Overexpressed Tumor Cell Activatable Albumin-Binding Doxorubicin Prodrug for Cancer-Targeted Therapy 2021 ·Pharmaceutics ·Hanhee Cho, Man Kyu Shim, Suah Yang, Sukyung Song, Yujeong Moon, Jinseong Kim, Youngro Byun, Cheol‐Hee Ahn, Kwangmeyung Kim	22
16	Visible-Light-Triggered Prodrug Nanoparticles Combine Chemotherapy and Photodynamic Therapy to Potentiate Checkpoint Blockade Cancer Immunotherapy 2021 ·ACS Nano ·Jiwoong Choi, Man Kyu Shim, Suah Yang, Hee Sook Hwang, Hanhee Cho, Jeongrae Kim, Wan Su Yun, Yujeong Moon, Jinseong Kim, Hong Yeol Yoon, Kwangmeyung Kim	143
17	Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity 2021 ·Biomaterials ·Suah Yang, Man Kyu Shim, (unknown), Jiwoong Choi, Gi‐Hoon Nam, Soo Hyun Kim, Jinseong Kim, Yujeong Moon, Han Young Kim, Jooho Park, Yoon Park, In-San Kim, Ju Hee Ryu, Kwangmeyung Kim	121
18	The safe and effective intraperitoneal chemotherapy with cathepsin B-specific doxorubicin prodrug nanoparticles in ovarian cancer with peritoneal carcinomatosis 2021 ·Biomaterials ·Jinseong Kim, Man Kyu Shim, Young‐Jae Cho, Sang‐Min Jeon, Yujeong Moon, Jiwoong Choi, Soo Hyun Kim, Jaewan Lee, (unknown), Jeong‐Won Lee, Kwangmeyung Kim	45
19	In Situ One-Step Fluorescence Labeling Strategy of Exosomes via Bioorthogonal Click Chemistry for Real-Time Exosome Tracking In Vitro and In Vivo 2020 ·Bioconjugate Chemistry ·Sukyung Song, Man Kyu Shim, Seungho Lim, Yujeong Moon, Suah Yang, Jinseong Kim, Yeonsun Hong, Hong Yeol Yoon, In-San Kim, Kwang Yeon Hwang, Kwangmeyung Kim	82
20	Cancer-specific drug-drug nanoparticles of pro-apoptotic and cathepsin B-cleavable peptide-conjugated doxorubicin for drug-resistant cancer therapy 2020 ·Biomaterials ·Man Kyu Shim, Yujeong Moon, Suah Yang, Jinseong Kim, Hanhee Cho, Seungho Lim, Hong Yeol Yoon, Joon‐Kyung Seong, Kwangmeyung Kim	85

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact